Investigation of Genetic Disease Marker Associated With Spontaneous Haemorrhagic Stroke Complicating Severe Pre-eclampsia in Pregnancy

March 13, 2023 updated by: Ildar Fakhradiyev, Asfendiyarov Kazakh National Medical University

Preventive and Personalized Medicine (2021-2023)

To search for a genetic marker of hemorrhagic stroke complicating severe eclampsia, a single nucleotide polymorphism (SNP) analysis of DNA obtained from the peripheral blood of patients with hemorrhagic stroke and normal control will be performed.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

Detailed Description:

Unrelated Korean subjects who have Spontaneous hemorrhagic stroke complicating severe eclampsia in pregnancy were recruited in the current study. Genotyping for various SNP associated due to the linkage disequilibrium patterns is to be performed. Genotypes would be statistically compared between patients with hemorrhagic stroke and normal control subjects free of hemorrhagic stroke

Study Type

Observational

Enrollment (Actual)

100

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 45 years (Adult)

Accepts Healthy Volunteers

N/A

Genders Eligible for Study

Female

Sampling Method

Probability Sample

Study Population

patients with hemorrhagic stroke complicating severe eclampsia in pregnancy who visited Scientific Center for Obstetrics, Gynecology and Perinatology. Kazakhstan, Almaty

Description

Inclusion Criteria:

-patients with hemorrhagic stroke complicating severe eclampsia in pregnancy

Exclusion Criteria:

patients without hemorrhagic stroke complicating severe eclampsia in pregnancy

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Experimental group:
patients with hemorrhagic stroke complicating severe pre-eclampsia in pregnancy
Genetic: SNP analysis of the DNA
SNP analysis of the DNA obtained from peripheral blood sample
Control group
patients without hemorrhagic stroke complicating severe pre-eclampsia in pregnancy
Genetic: SNP analysis of the DNA
SNP analysis of the DNA obtained from peripheral blood sample

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
genotyping for the SNP associated with hemorrhagic stroke complicating severe eclampsia in pregnancy
Time Frame: 1 year
1 year

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Asfendiyarov Kazakh National Medical University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

October 23, 2021

Primary Completion (Actual)

January 20, 2023

Study Completion (Actual)

January 20, 2023

Study Registration Dates

First Submitted

October 21, 2021

First Submitted That Met QC Criteria

November 14, 2021

First Posted (Actual)

November 16, 2021

Study Record Updates

Last Update Posted (Actual)

March 14, 2023

Last Update Submitted That Met QC Criteria

March 13, 2023

Last Verified

March 1, 2023

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 1189

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Eclampsia

Clinical Trials on SNP analysis of the DNA

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Netherlands

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe